

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Digilab, Inc.		11/30/2007	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Harvard Bioscience, Inc.		
Street Address:	84 October Hill Rd.		
City:	Holliston		
State/Country:	MASSACHUSETTS		
Postal Code:	01746		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	2835699	BIOVISION	
Registration Number:	2995443	BIOVISION	
Registration Number:	2797432	BIOVISION	
Registration Number:	2995452	BIOVISION	
Registration Number:	2641178	DIFFERENTIAL PEPTIDE DISPLAY	
Registration Number:	2780988	PEPTIDOMICS	
Registration Number:	2781068	SPECTROMANIA	
CORRESPONDENCE DATA			
Fax Number:	(248)351-3082		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	(734) 222-4776		
Email:	jbisdorf@jaffelaw.com		
Correspondent Name:	Jeremy D. Bisdorf		
Address Line 1:	201 S. Main St., Suite 300		
Address Line 4:	Ann Arbor, MICHIGAN 48104		

CH \$190.00 2835699

ATTORNEY DOCKET NUMBER:	HARBIO-CAPIT
NAME OF SUBMITTER:	Jeremy D. Bisdorf
Signature:	/jdb/
Date:	04/03/2008

Total Attachments: 9
source=HARBLOTM#page1.tif
source=HARBLOTM#page2.tif
source=HARBLOTM#page3.tif
source=HARBLOTM#page4.tif
source=HARBLOTM#page5.tif
source=HARBLOTM#page6.tif
source=HARBLOTM#page7.tif
source=HARBLOTM#page8.tif
source=HARBLOTM#page9.tif

Exhibit B

PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (this "Agreement"), is made and entered into as of November 30, 2007 by Digilab, Inc , a Delaware corporation ("Digilab"), in favor of Harvard Bioscience, Inc , a Delaware corporation ("Harvard")

Digilab and Harvard, among others, are parties to that certain Asset Purchase Agreement of even date herewith, pursuant to which Digilab, directly and through one or more of its subsidiaries, agreed to purchase the Assets from Harvard, directly and through one or more of its subsidiaries (the "Purchase Agreement") Any capitalized terms used but not defined in this Agreement shall have the meanings assigned to such terms in the Purchase Agreement

Pursuant to Section 5.08 of the Purchase Agreement, Digilab has agreed to grant Harvard a first priority security interest (subject to the limitations set forth in Section 5.09 of the Purchase Agreement) in the Collateral (defined below) in order to secure Digilab's obligations arising under the Purchase Agreement with respect to the Earn-Out, including, but not limited to the Earn-Out Promissory Notes

In order to secure the prompt satisfaction by Digilab of all of its obligations to Harvard under the Purchase Agreement with respect to the Earn-Out, the Earn-Out Promissory Notes and this Agreement, Digilab has agreed to execute and deliver a certain Pledge and Security Agreement, dated of even date herewith (the "PSA") and to grant Harvard a continuing security interest in the Collateral as more fully set forth below. The PSA contemplates execution of this Agreement

Accordingly, the parties hereto agree as follows:

1 Definitions; Interpretation

a Terms Defined in PSA All capitalized terms used in this Agreement (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the PSA

b Certain Defined Terms As used in this Agreement, the following terms shall have the following meanings:

"Collateral" has the meaning set forth in Section 2

"PIO" means the United States Patent and Trademark Office.

"Secured Obligations" has the meaning set forth in the PSA

"UCC" means the Uniform Commercial Code as the same may, from time to time, be in effect in The Commonwealth of Massachusetts.

c. Terms Defined in UCC Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the meanings assigned to them in the UCC; provided, however, that to the extent that the UCC is used to define any term herein and such term is defined differently in different Articles of the UCC, the definition of such term contained in Article 9 of the UCC shall govern

2. Security Interest

a. Grant of Security Interest As security for the payment and performance of the Secured Obligations, Digilab hereby grants, assigns, and conveys to Harvard a security interest in all of Digilab's right, title and interest in, to and under the following property, in each case whether now or hereafter existing or arising or in which Digilab now has or hereafter owns, acquires or develops an interest and wherever located (collectively, the "Collateral"):

i. all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such patents and patent applications as described in Schedule A), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

ii. all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such marks, names and applications as described in Schedule B), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

iii. the entire goodwill of or associated with the businesses now or hereafter conducted by Digilab connected with and symbolized by any of the aforementioned properties and assets;

iv. all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;

v. all accounts, all intangible intellectual or other similar property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not Harvard is the loss payee thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and

vi. all products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral

b Continuing Security Interest Digilab agrees that this Agreement shall create a continuing security interest in the Collateral which shall remain in effect until terminated in accordance with Section 20

3 Supplement to PSA The terms and provisions of this Agreement are intended as a supplement to the terms and provisions of the PSA. Digilab acknowledges that the rights and remedies of Harvard with respect to the security interest in the Collateral granted hereby are more fully set forth in the PSA and all such rights and remedies are cumulative

4 Representations and Warranties Digilab represents and warrants to Harvard that:

a Patents A true and correct list of all of the existing Collateral consisting of U S patents and patent applications and/or registrations owned by Digilab, in whole or in part, is set forth in Schedule A.

b Trademarks A true and correct list of all of the existing Collateral consisting of U S trademarks, trademark registrations and/or applications owned by Digilab, in whole or in part, is set forth in Schedule B

5. Further Acts On a continuing basis, Digilab shall make, execute, acknowledge and deliver, and file and record in the proper filing and recording places, all such instruments and documents, and take all such action as may be necessary or advisable or may be requested by Harvard to carry out the intent and purposes of this Agreement, or for assuring, confirming or protecting the grant or perfection of the security interest granted or purported to be granted hereby, to ensure Digilab's compliance with this Agreement or to enable Harvard to exercise and enforce its rights and remedies hereunder with respect to the Collateral, including any documents for filing with the PIO and/or any applicable state office. Harvard may record this Agreement, an abstract thereof, or any other document describing Harvard's interest in the Collateral with the PIO, at the expense of Digilab

6 Future Rights Except as otherwise expressly agreed to in writing by Harvard, if and when Digilab shall obtain rights to any new patentable inventions or any new trademarks, or become entitled to the benefit of any of the foregoing, or obtain rights or benefits with respect to any reissue, division, continuation, renewal, extension or continuation-in-part of any patents or trademarks, or any improvement of any patent, the provisions of Section 2 shall automatically apply thereto and Digilab shall give to Harvard prompt notice thereof. Digilab shall do all things deemed necessary or advisable by Harvard to ensure the validity, perfection, priority and enforceability of the security interests of Harvard in such future acquired Collateral. Digilab hereby authorizes Harvard to modify, amend, or supplement the Schedules hereto and to re-execute this Agreement from time to time on Digilab's behalf and as its attorney-in-fact to include any such future Collateral and to cause such reexecuted Agreement or such modified, amended or supplemented Schedules to be filed with the PIO

7 Harvard Appointed Attorney-in-Fact Harvard shall have the right to, in the name of Digilab, or in the name of Harvard or otherwise, without notice to or assent by Digilab, and Digilab hereby constitutes and appoints Harvard (and any of Harvard's officers or employees or agents designated by Harvard) as Digilab's true and lawful attorney-in-fact, with full power and

authority, and hereby authorizes Harvard: (i) to sign and file in the name of Digilab any financing statement (with or without Digilab's signature) or other instrument and any modification, supplement or amendment to this Agreement (including any described in Section 6), and to sign the name of Digilab on all or any of such documents or instruments and perform all other acts that Harvard deems necessary or advisable in order to perfect or continue perfected, maintain the priority or enforceability of or provide notice of Harvard's security interest in, the Collateral; and (ii) to execute any and all other documents and instruments, and to perform any and all acts and things for and on behalf of Digilab, which Harvard may deem necessary or advisable to maintain, preserve and protect the Collateral and to accomplish the purposes of this Agreement, including after the occurrence and during the continuance of any Event of Default (A) to defend, settle, adjust or institute any action, suit or proceeding with respect to the Collateral, (B) to assert or retain any rights under any license agreement for any of the Collateral, including any rights of Digilab arising under Section 365(n) of the Bankruptcy Code, and, (C) to execute any and all applications, documents, papers and instruments for Harvard to use the Collateral, to grant or issue any exclusive or non-exclusive license with respect to any Collateral, and to assign, convey or otherwise transfer title in or dispose of the Collateral; provided, however, that in no event shall Harvard have the unilateral power, prior to the occurrence and continuance of an Event of Default, to assign any of the Collateral to any Person, including itself, without Digilab's written consent. The foregoing power of attorney is coupled with an interest and irrevocable so long as Harvard has any Secured Obligations that have not been paid and performed in full. Digilab hereby ratifies, to the extent permitted by law, all that Harvard shall lawfully and in good faith do or cause to be done by virtue of and in compliance with this Section 7.

8 Harvard Performance of Digilab Obligations Harvard may perform or pay any obligation which Digilab has agreed to perform or pay under or in connection with this Agreement, and Digilab shall reimburse Harvard on demand for any amounts paid by Harvard pursuant to this Section 8

9 Harvard's Duties Notwithstanding any provision contained in this Agreement, Harvard shall have no duty to exercise any of the rights, privileges or powers afforded to it and shall not be responsible to Digilab or any other Person for any failure to do so or delay in doing so. Except for and the accounting for moneys actually received by Harvard hereunder, Harvard shall have no duty or liability to exercise or preserve any rights, privileges or powers pertaining to the Collateral

10 Remedies Upon the occurrence and during the continuance of any Event of Default, Harvard shall have, in addition to all other rights and remedies granted to it in this Agreement or the PSA, all rights and remedies of a secured party under the UCC and other applicable laws. Without limiting the generality of the foregoing, Digilab agrees that Harvard shall at all times have such royalty free licenses, to the extent permitted by law, for any Collateral that is reasonably necessary to permit the exercise of any of Harvard's rights or remedies upon or after the occurrence and during the continuance of an Event of Default. In addition to and without limiting any of the foregoing, upon the occurrence and during the continuance of an Event of Default, Harvard shall have the right but shall in no way be obligated to bring suit, or to take such other action as Harvard deems necessary or advisable, in the name of Digilab or Harvard, to enforce or protect any Collateral, and any license thereunder, in which event Digilab shall, at the

request of Harvard, do any and all lawful acts and execute any and all documents required by Harvard in aid of such enforcement

11. Notices All notices, requests or demands required or permitted by this Agreement or any part of this Agreement shall be given pursuant to Section 10.02 of the Purchase Agreement

12. No Waiver; Cumulative Remedies No failure on the part of Harvard to exercise, and no delay in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights and remedies under this Agreement are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be available to Harvard

13. Binding Effect. The terms of this Agreement shall be binding upon and inure to the benefit of the representatives, successors and assigns of the parties

14. Governing Law; Consent to Jurisdiction This Agreement shall be construed, interpreted and enforced in accordance with the laws of The Commonwealth of Massachusetts without consideration of principles of conflicts or choice of laws

15. Entire Agreement; Amendment This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and shall not be amended except by the written agreement of the parties as provided in the Credit Agreement

16. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction

17. Counterparts This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

18. Incorporation of Provisions of the PSA To the extent the PSA contains provisions of general applicability to the Secured Obligations or the Collateral, such provisions are incorporated herein by this reference

19. No Inconsistent Requirements. Digilab acknowledges that this Agreement and the other documents relating to the Secured Obligations and the Collateral may contain covenants and other terms and provisions variously stated regarding the same or similar matters, and agrees that all such covenants, terms and provisions are cumulative and all shall be performed and satisfied in accordance with their respective terms

20 Termination Upon the termination of the PSA and payment and performance in full of all Secured Obligations, the security interests contemplated by this Agreement shall terminate and Harvard shall promptly execute and deliver to Digilab such documents and instruments reasonably requested by Digilab as shall be necessary to evidence termination of all security interests given by Digilab to Harvard hereunder, including cancellation of this Agreement by written notice from Harvard to the PTO

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement,
as of the date first above written


DIGILAB:

DIGILAB, INC

By: _____
Name:
Title:

HARVARD:

HARVARD BIOSCIENCE, INC

By: 
Name: David Green
Title: President

[Signature Page for Patent and Trademark Security Agreement - 38]

IN WIINESS WHEREOF, the parties hereto have duly executed this Agreement,
as of the date first above written

DIGILAB:

DIGILAB, INC

By: 

Name: Sidney Braginsky

Title: Chief Executive Officer

HARVARD:

HARVARD BIOSCIENCE, INC

By: _____

Name: David Green

Title: President

[Signature Page for Patent and Trademark Security Agreement - 38]

TRADEMARK REGISTRATIONS

Registration No.	Registration Date	Mark
2,835,699	April 27, 2004	BIOVISION
2,995,443	September 13, 2005	BIOVISION
2,797,432	December 23, 2003	BIOVISION (& Design)
2,995,452	September 13, 2005	BIOVISION (& Design)
2,641,178	October 22, 2002	DIFFERENTIAL PEPTIDE DISPLAY
2,780,988	November 11, 2003	PEPTIDOMICS
2,781,068	November 11, 2003	SPECTROMANIA